Vivos Therapeutics annual depreciation and amortization
2019
2020
2021
2022
2023
2024
2025
Vivos Therapeutics Depreciation & Amortization Growth & History (VVOS)
Vivos Therapeutics's depreciation and amortization was $1.3M for fiscal 2025.
View full Vivos Therapeutics company overviewVivos Therapeutics annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.3M | $728,000 | +125.30% |
| 2024 | 2024-12-31 | $581,000 | −$40,000 | −6.44% |
| 2023 | 2023-12-31 | $621,000 | −$48,000 | −7.17% |
| 2022 | 2022-12-31 | $669,000 | −$64,000 | −8.73% |
| 2021 | 2021-12-31 | $733,000 | $15,000 | +2.09% |
| 2020 | 2020-12-31 | $718,000 | −$33,228 | −4.42% |
| 2019 | 2019-12-31 | $751,228 | — | — |
Vivos Therapeutics quarterly depreciation and amortization
Q1.20
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $510,000 | $204,000 | +66.67% |
| Q1 2026 | 2026-03-31 | $454,000 | $277,000 | +156.50% |
| Q4 2025 | 2025-12-31 | $442,000 | — | — |
| Q3 2025 | 2025-09-30 | $384,000 | $238,000 | +163.01% |
| Q2 2025 | 2025-06-30 | $306,000 | $161,000 | +111.03% |
| Q1 2025 | 2025-03-31 | $177,000 | $31,000 | +21.23% |
| Q3 2024 | 2024-09-30 | $146,000 | −$4,000 | −2.67% |
| Q2 2024 | 2024-06-30 | $145,000 | −$3,000 | −2.03% |
| Q1 2024 | 2024-03-31 | $146,000 | −$29,000 | −16.57% |
| Q3 2023 | 2023-09-30 | $150,000 | −$25,000 | −14.29% |
| Q2 2023 | 2023-06-30 | $148,000 | −$14,000 | −8.64% |
| Q1 2023 | 2023-03-31 | $175,000 | $134,000 | +326.83% |
| Q3 2022 | 2022-09-30 | $175,000 | −$18,000 | −9.33% |
| Q2 2022 | 2022-06-30 | $162,000 | −$33,000 | −16.92% |
| Q1 2022 | 2022-03-31 | $41,000 | −$136,000 | −76.84% |
| Q3 2021 | 2021-09-30 | $193,000 | $14,067 | +7.86% |
| Q2 2021 | 2021-06-30 | $195,000 | $14,361 | +7.95% |
| Q1 2021 | 2021-03-31 | $177,000 | −$3,968 | −2.19% |
| Q3 2020 | 2020-09-30 | $178,933 | — | — |
| Q2 2020 | 2020-06-30 | $180,639 | — | — |
| Q1 2020 | 2020-03-31 | $180,968 | — | — |
Vivos Therapeutics depreciation and amortization trends
Over the last five fiscal years, Vivos Therapeutics's depreciation and amortization increased from $718,000 to $1.3M, a change of $591,000. The latest reported quarter, Q2 2026, shows $510,000.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Vivos Therapeutics source filings ↗